Neuland Laboratories Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹776.25 crore, reflecting a quarter-on-quarter *(QoQ) increase of 76.54 per cent from ₹439.71 crore. This corresponds to a year-on-year *(YoY) growth of 136.40 per cent.
Operating Profit
Operating Profit stands at ₹307.33 crore, reflecting a quarter-on-quarter *(QoQ) increase of 298.46 per cent from ₹77.13 crore. This corresponds to a year-on-year *(YoY) growth of 501.78 per cent.
PBDT
PBDT stands at ₹312.58 crore, reflecting a quarter-on-quarter *(QoQ) increase of 298.75 per cent from ₹78.39 crore. This corresponds to a year-on-year *(YoY) growth of 456.29 per cent.
Profit Before Tax
Profit Before Tax stands at ₹287.49 crore, reflecting a quarter-on-quarter *(QoQ) increase of 427.80 per cent from ₹54.47 crore. This corresponds to a year-on-year *(YoY) growth of 631.53 per cent.
Net Profit
Net Profit stands at ₹212.67 crore, reflecting a quarter-on-quarter *(QoQ) increase of 424.21 per cent from ₹40.57 crore. This represents a 664.72 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Neuland Laboratories Ltd Earnings
- YOY
- QOQ
Neuland Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Neuland Laboratories Ltd Research Reports
Neuland Laboratories Ltd Financial Reports
Neuland Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Neuland Labs. | -0.70% | 4.45% | 11.85% | 42.65% | 25.45% | 57.24% |
| Wockhardt | -0.55% | -0.55% | -6.49% | 52.11% | 33.44% | 12.25% |
| Acutaas Chemical | -0.31% | 3.67% | 16.27% | 66.09% | 107.94% | 227.84% |
| Sai Life | 1.82% | 0.95% | 8.63% | 33.40% | 31.99% | 59.10% |
| Piramal Pharma | 4.21% | 5.55% | 3.75% | 24.31% | -1.68% | -13.61% |
| Rubicon Research | -5.00% | -8.14% | 0.47% | 67.78% | 95.65% | 107.63% |
| Pfizer | 3.20% | 3.99% | 3.56% | -5.43% | -5.98% | -20.89% |
Company Info
Company Information
Executive Chairman : D R Rao
Non Executive Director : Christopher M Cimarusti
Vice Chairman & Chief Executive Officer : D Sucheth Rao
Vice Chairman & Managing Director : D Saharsh Rao
Company Sec. & Compli. Officer : Sarada Bhamidipati
Independent Director : Homi Rustam Khusrokhan
Independent Director : Prasad R Menon
Independent Director : Sugata Sircar
Independent Director : Pallavi Joshi Bakhru
Additional Director : Ravi Gopinath